menù
Phase: Phase II-III clinical trials
Principal Investigator: Dr. Lo Russo Giuseppe
Main Facility: Thoracic Oncology Unit
Drug: R-DXd (raludotatug deruxtecan) I-DXd (ifinatamab deruxtecan) Docetaxel
Drug: Pembrolizumab Mk2870 (sacituzumab tirumotecan) Chemio: Carboplatin, cisplatin, pemetrexed, paclitaxel, gemcitabine (based on squamous or non-squamous histology)
Main Facility: Medical Oncology 1 – Medical Oncology Unit: Melanoma
Drug: Darovasertib, Crizotinib Nivolumab, Ipilimumab, Pembrolizumab, Dacarbazina
Phase: Phase IV clinical trials
Principal Investigator: Prof. Mazzaferro Vincenzo
Main Facility: Oncologic Surgery 1 – Hepato-Gastro-Pancreatic and Liver Transplantation
Phase: Phase III clinical trials
Principal Investigator: Dr. Pietrantonio Filippo
Main Facility: Gastrointestinal Oncology
Drug: Gemcitabina + Nab-paclitaxel vs mFOLFIRINOX
Phase: Phase I-II clinical trials
Principal Investigator: Dott.ssa Bianchi Giulia Valeria
Main Facility: Medical Oncology 1
Drug: Cohort A: STX-478 Cohort B: STX-478 + fulvestrant or STX-478 + letrozole/anastrozole/exemestane Cohort C/D/E: STX-478 + endocrine therapy + CDK4/6 inhibitor
Principal Investigator: Prof. Vernieri Claudio
Drug: Atezolizumab
Phase: Phase II clinical trials
Drug: Panitumumab, 5-Fluorouracile, Sotorasib
Principal Investigator: Dott.ssa Rusconi Chiara
Main Facility: Haematology
Drug: Tislelizumab (BGB-A317)
Drug: Pembrolizumab Chemoterapy: -paclitaxel+cisplatin or carboplatin -pemetrexed + cisplatin or carboplatin
Principal Investigator: Dott. Alfieri Salvatore
Main Facility: Medical Oncology 3 – Head and Neck Cancers
Drug: Gemcitabina 1000 mg/mq Cisplatino 100 mg/mq Radioterapia Capecitabina 650 mg/mq
Principal Investigator: Dr. Procopio Giuseppe
Main Facility: Genitourinary Medical Oncology
Drug: all drugs in clinical practice group A (dual immunotherapy NIVO + IPI Q4W) group B (immunotherapy + anti-angiogenic)
Main Facility: Diagnostic and Interventional Radiology Unit
Drug: Doxorubicin
Principal Investigator: Dr. Mazzeo Laura
Drug: Zongertinib
Principal Investigator: Prof. De Braud Filippo
Drug: Atezolizumab, Futibatinib, Amivantamab
Principal Investigator: Dott.ssa Giannatempo Patrizia
Drug: Enfortumab Vedotin, Pembrolizumab
Drug: Patritumab Deruxtecan
Principal Investigator: Prof. Corradini Paolo
Drug: Obinutuzumab
Drug: Arm A: MK-2870 Arm B: MK-2870+Pembrolizumab Arm C: Paclitaxel/ Nab-Paclitaxel/ Capecitabine/ Liposomal Doxorubicin
Sign up for our newsletter to stay informed about news, events, and updates from the Institute
Subscribe